Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.

Item

http://www.wikidata.org/entity/Q38733649

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.

@en

type

Item

label

Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.

@en

prefLabel

Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.

@en

P1476

Synergistic Effect of SH003 and Doxorubicin in Triple-negative Breast Cancer.

@en

P2093

Ah Jeong Kim

http://www.w3.org/2001/XMLSchema#string

Sang-Mi Woo

http://www.w3.org/2001/XMLSchema#string

Seong-Gyu Ko

http://www.w3.org/2001/XMLSchema#string

Sung-Gook Cho

http://www.w3.org/2001/XMLSchema#string

Youn Kyung Choi

http://www.w3.org/2001/XMLSchema#string

Young Cheol Shin

http://www.w3.org/2001/XMLSchema#string

P2860

Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents

Doxorubicin in combination with a small TGFbeta inhibitor: a potential novel therapy for metastatic breast cancer in mouse models

Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial.

Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling.

Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer.

Triple-negative breast cancer: clinical features and patterns of recurrence.

Paclitaxel resistance: molecular mechanisms and pharmacologic manipulation.

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

P304

1817-1823

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PTR.5687

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27476488

http://www.w3.org/2001/XMLSchema#string